Biotechnology firm Biocon said its partner Mylan has re-submitted marketing authorisation applications with the European drug regulator European Medicines Agency for two biosimilars Trastuzumab and Pegfilgrastim, reports PTI from New Delhi.
Published 07 November 2017, 15:46 IST